Welcome to our dedicated page for Bullfrog AI Holdings news (Ticker: BFRGW), a resource for investors and traders seeking the latest updates and insights on Bullfrog AI Holdings stock.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) generates news at the intersection of artificial intelligence, bioinformatics, and pharmaceutical development. This page aggregates coverage related to the company’s AI-driven platforms for drug discovery and clinical trial optimization, giving readers a focused view of how its technology is being applied and discussed across the life sciences sector.
Company announcements highlight the use of its proprietary bfLEAP ae analytics engine, bfPREP ae data preparation module, and BullFrog Data Networks ae platform in real-world settings. Recent news includes precision-oncology analyses in pancreatic adenocarcinoma, where BullFrog AI reports identifying patient subgroups with an almost threefold increase in mean survival in glufosfamide trial data, as well as an accepted abstract and poster presentation at the ASCO Gastrointestinal Cancers Symposium.
Investors and industry observers can also follow updates on commercial collaborations, such as the company’s work with Eleison Pharmaceuticals on late-stage oncology data and its partnership with Sygnature Discovery to introduce BullFrog Data Networks ae to global biopharma clients. Additional news items cover technical conference presentations, whitepapers on AI in bioinformatics, and webinars that detail how BullFrog AI operationalizes human-in-the-loop AI agents in clinical data workflows.
By reviewing the news feed for BFRG and BFRGW, readers can track developments in BullFrog AI’s scientific validation efforts, commercial initiatives, and regulatory disclosures. This page provides a centralized view of press releases and related articles for those monitoring the company’s role in AI-enabled drug development.
BullFrog AI (NASDAQ: BFRG) announced a commercial agreement dated March 30, 2026 with a top-5 global pharmaceutical company to apply its bfLEAP® platform to identify and prioritize novel therapeutic targets in major depressive disorder (MDD). The deal includes exclusive access to a target candidate and positions BullFrog AI as a partner in the Customer’s discovery and clinical development program for MDD.
The release cites the MDD market at >$8 billion in 2025 and rising toward >$11 billion by 2032, and notes the company will file a Form 8-K with additional agreement details.
BullFrog AI (NASDAQ: BFRG) unveiled bfARENAS™, a scenario-based decision engine to strengthen its end-to-end AI intelligence workflow for drug target discovery and clinical trial strategy.
The tool frames strategic scenarios as inputs to generate transparent, risk-balanced R&D portfolio recommendations. A webinar on bfARENAS™ is scheduled for March 27, 2026 at 11 a.m. ET.
BullFrog AI (NASDAQ: BFRG) will host a webinar on March 27, 2026 at 11 a.m. ET to introduce a new precision AI scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. The capability complements bfPREP and bfLEAP by adding a strategic decision‑support layer.
The platform compares drug programs and trial designs without arbitrary scores, tests decisions against multiple scenarios, and produces auditable, assumption‑driven outputs to support governance, cross‑functional alignment, and trial optimization.
BullFrog AI (NASDAQ: BFRG) will launch a new scenario-based decision engine on March 25, 2026 to augment its bfPREP and bfLEAP platforms. The capability evaluates drug programs, trial designs, and strategic portfolio options across explicit scenarios to surface robust, risk-balanced R&D portfolios.
Key features include multi-scenario testing (e.g., capital-constrained, US-first, global), preservation of portfolio diversity, and identification of programs that succeed across multiple strategic futures.
BullFrog AI (NASDAQ: BFRG) published a white paper, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” dated January 27, 2026. The paper explains how BullFrog’s bfPREP platform converts noisy, document-heavy biomedical data into standardized, AI-ready datasets by recognizing reliable patterns and producing clinically contextualized formats. It presents a three-pillar harmonization framework: (1) engineering clinically meaningful derived features, (2) producing reliable categorical variables and harmonized schemas, and (3) converting unstructured clinical documents into analysis-ready tables. The company positions bfPREP as the first step in its analytical toolkit to reduce time spent data-wrangling and support decision-making in drug development.
BullFrog AI (NASDAQ: BFRG) reported that its bfLEAP® platform identified treatment-effect heterogeneity and key biomarkers in a post-hoc analysis of the randomized phase 3 trial TH-CR-302, finding an almost threefold increase in mean survival from control to treatment arms in specific pancreatic cancer subgroups.
Findings will be presented at the ASCO GI Symposium on Jan. 9, 2026 (poster B) and will appear in the Journal of Clinical Oncology supplement. The analysis, conducted with Eleison Pharmaceuticals and Moffitt Cancer Center authors, highlights bfLEAP® and bfPREP™ as tools for data-driven patient clustering, early predictor identification, and precision-oncology stratification in glufosfamide development.
BullFrog AI (NASDAQ: BFRG) published its 2025 annual letter highlighting commercialization progress, technology milestones and 2026 catalysts. Key developments include a signed commercial collaboration with Sygnature Discovery expected to generate significant revenue through 2028, a real-world deployment with Eleison Pharmaceuticals in a pivotal Phase 3 oncology program, and the launch of bfPREP, an AI data‑preparation module that the company says can reduce data prep timelines from months to days. The company reports an annual burn of approximately $6.2 million and has financing flexibility via a $10 million equity line and an ATM. Near-term catalysts include the public presentation of Eleison results at ASCO on January 9, 2026 and ongoing advanced discussions with large pharmaceutical partners.
BullFrog AI (NASDAQ: BFRG) published a whitepaper on Nov 18, 2025 titled “AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks.”
The paper describes how bfLEAP and BullFrog Data Networks address three bioinformatics pitfalls: the compositional data trap, misleading feature importance, and generative AI overreach. It highlights causal inference and probabilistic validation to generate reproducible insights across genomics, transcriptomics, proteomics, and clinical data for target ID, biomarker discovery, and patient stratification.
BullFrog AI (NASDAQ: BFRG) will present a technical talk titled "Human-in-the-Loop Agent Workflows with bfPREP™" at the AI Drug Discovery & Development Summit 2025 in Boston, November 18–20, 2025.
The presentation is part of Technical Insights Session 1 on Wednesday, November 19, 2025 and will describe how bfPREP™ operationalizes AI agents for reliable, reproducible data preparation in drug development, including structured outputs, stable schemas, and human validation. bfPREP™ is BullFrog AI’s data cleansing and preparation module within BullFrog Data Networks™, focused on clinical, omics, and real-world data.
The summit expects 500+ attendees and 100+ speakers and targets AI applications across discovery through clinical development.
BullFrog AI (NASDAQ: BFRG) announced an abstract accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, Jan 8–10, 2026 in San Francisco.
The poster, titled “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” will be presented in Poster Session B on January 9, 2026 and published in the ASCO GI online proceedings and the Journal of Clinical Oncology supplement. The study, co-authored with Eleison Pharmaceuticals and investigators at Moffitt Cancer Center, uses BullFrog AI’s bfLEAP and bfPREP platforms to identify patient subtypes with potential enhanced response to glufosfamide.